据港交所12月23日披露，Frontera Therapeutics向港交所主板递交上市申请书，UBS Securities HongKong Limited、海通国际资本有限公司为其联席保荐人。 招股书显示，自2019年成立以来，公司一直致力于自主开发创新的重组腺相关病毒("rAAV")基因疗法。该公司已开发出一条差异化且临床进展领先的管线， 具全球同类最佳潜力，特别是针对眼科及心血管疾病。 | : [編纂]股股份(視 | [編纂]項下 編纂 數目 | 與否而定) | | | | | --- | --- | --- | --- | --- | --- | | [編纂]數目 | [編纂]股股份(可 | . . | [編纂]數目 | . | [編纂]股股份(可予 | | 行使與否而定) | 每股[編纂][編纂] | ... | 一篇■【端篇】 | | | | 紀佣金、0.0027 | 0.00565% 聯交月 | | | | | | 財局交易徵費( | 足,多繳款項可 | | | | | | . | 每股股份0.0001美 | 向 個 | [編纂] | .. | 【編纂】 | | 聯席保薦人、[編纂]、 | [ ...

智通财经APP获悉，据港交所12月23日披露，Frontera Therapeutics向港交所主板递交上市申请书，UBS Securities HongKong Limited、海通国际资本有限公司 为其联席保荐人。招股书显示，自2019年成立以来，公司一直致力于自主开发创新的重组腺相关病毒("rAAV")基因疗法。该公司已开发出一条差异化且临床 进展领先的管线，具全球同类最佳潜力，特别是针对眼科及心血管疾病。 截至最后实际可行日期(2025年12月16日)，Frontera Therapeutics的产品管线包括八款自主开发的rAAV基因治疗候选药物，包括(i)两款核心产品，即FT- 002(一种正在研究用于治疗X连锁视网膜色素变性("XLRP")的潜在全球同类最佳候选药物)及FT-003(一款潜在全球同类最佳候选药物，正在研究用于透过玻 璃体内注射治疗新生血管性老年性黄斑病变("nAMD")及糖尿病黄斑水肿("DME");(ii)一款关键产品，即FT-001(一种用于治疗RPE65基因双等位基因突变导致 的遗传性视网膜疾病("IRD")("RPE65mIRD"或"RPE65介导的IRD")的基因治疗候选 ...

智通财经获悉，据港交所12月23日披露，Frontera Therapeutics向港交所主板递交上市申请书，UBS Securities HongKong Limited、海通国际资本有限公司为其联席保荐人。据招股书，Frontera Therapeutics 是一家处于临床阶段的基因治疗公司，专注于创新疗法的研发，具有国际化业务布局，致力于为世界各 地的患者提供安全、有效且可负担的基因治疗方案。自2019年成立以来，公司一直致力于自主开发创新 的重组腺相关病毒("rAAV")基因疗法。该公司已开发出一条差异化且临床进展领先的管线，具全球同类 最佳潜力，特别是针对眼科及心血管疾病。 本文源自：智通财经网 ...

[繼臺] 据港交所12月23日披露，Frontera Therapeutics向港交所主板递交上市申请书，UBS Securities HongKong Limited、海通国际资本有限公司为其联席保荐, 据招股书，Frontera Therapeutics是一家处于临床阶段的基因治疗公司，专注于创新疗法的研发，具有国际化业务布局，致力于为世界各地的患 有效且可负担的基因治疗方案。自2019年成立以来，公司一直致力于自主开发创新的重组腺相关病毒("itAAV")基因疗法。该公司已开发出一 进展领先的管线，具全球同类最佳潜力，特别是针对眼科及心血管疾病。 Frontera Therapeutics (於 開曼 群島註冊成立之有限公司) | | | UBS 瑞銀集團 「編纂]股股份(可- 「編纂]股股份(可予 行使與否而定) 每 股[ 編 纂] 編 纂] 最高 | 經 | 紀 佣 金、0.0027' 0.00565% 聯交 戶 財局交易徵費( 足,多繳款項可 每股股份0.0001美 [編纂] 聯席保薦 , | 編纂】, ...

Frontera Therapeutics (於 開曼 群島註冊成立之有限公司) [編纂] 「編纂】項下「編纂】數目 [編纂]股股份(視: 智通财经APP获悉，据港交所12月23日披露，Frontera Therapeutics向港交所主板递交上市申请书，UBS Securities HongKong Limited、海通国际资本有限公司 为其联席保荐人。据招股书，Frontera Therapeutos是一家处于临床阶段的基因治疗公司，专注于创新疗法的研发，具有国际化业务布局，致力于为世界各地 的患者提供安全、有效且可负担的基因治疗方案。自2019年成立以来，公司一直致力于自主开发创新的重组腺相关病毒("trAAV")基因疗法。该公司已开发出 条差异化且临床进展领先的管线，具全球同类最佳潜力，特别是针对眼科及心血管疾病。 UBS 瑞銀集團 與否而定) 「編纂]股股份(可- 「編纂]股股份(可予 行使與否而定) 每股[編纂][編纂] 最高|編纂] 紀 佣 金、0.0027' 0.00565% 聯交 戶 財局交易徵費( 足,多繳款項可 每股股份0.0001美 [編畫] 滕席保唐 , | 編纂], ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Frontera Therapeutics （於開曼群島註冊成立的有限公司） 的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作提供資訊予香港公眾人士。 本 申 請 版 本 為 草 擬 本，其 內 所 載 資 料 並 不 完 整，亦 可 能 會 作 出 重 大 變 動。 閣 下 閱 覽 本 文 件，即 代 表 閣下知悉、接納並向本公司、其保薦人、整體協調人、顧問或承銷團成員表示同意： 本公司招股章程根據香港法例第32章《公司（清盤及雜項條文）條例》呈交香港公司註冊處處長登記前， 本 公 司 不 會 向 香 港 公 眾 人 士 提 出 要 約 或 邀 請。倘 於 適 當 時 候 向 香 港 公 眾 人 士 提 出 要 約 或 邀 請，準 投 資 者 務 請 僅 依 據 呈 交 香 港 公 司 註 冊 處 註 冊 的 ...

Group 1: Key Policies and Measures - Hubei Province's Medical Insurance Bureau and Health Commission launched 18 measures to support the high-quality development of innovative drugs, covering key aspects such as R&D support, inclusion in the medical insurance catalog, clinical application promotion, and strengthening payment systems [1][2][5] - The measures aim to alleviate public concerns regarding medical treatment and medication, while also establishing a solid foundation for the health industry in central China [1][5] Group 2: R&D and Innovation Support - The new measures extend the payment model from the end of the insurance process to the R&D phase, assisting pharmaceutical companies and research institutions in overcoming challenges and accelerating the market entry of effective drugs [2] - The initiative encourages commercial health insurance to invest in long-term capital through funds, alleviating the financial pressure on R&D for companies [2] Group 3: Access and Reimbursement - A dual-channel support system combining medical insurance and commercial insurance is being established to ensure innovative drugs are more accessible to the public [3] - The medical insurance department is committed to including all innovative drugs in the national medical insurance catalog and providing early intervention for eligible local innovative drugs [3] Group 4: Clinical Application and Training - The medical insurance department is optimizing processes to expedite the entry of innovative drugs into hospitals and directly to patients, including a green channel for drug listing and a two-month deadline for medical institutions to discuss new drug entries [4] - Training for healthcare professionals on the clinical use of innovative drugs will be conducted to ensure effective application and outcomes [4] Group 5: Market Expansion and Global Reach - The measures aim to create a multi-layered payment guarantee network, encouraging commercial insurance and mutual aid organizations to include innovative drugs in their coverage [5] - Hubei Province is actively promoting its innovative drugs in global markets, particularly in countries along the Belt and Road Initiative, enhancing the international influence of Hubei's pharmaceutical industry [5] Group 6: Commercial Insurance Directory - The first commercial health insurance innovative drug directory was published, focusing on high-value drugs that exceed the basic medical insurance's scope, including high-priced cancer drugs and gene therapies [6][7] - A total of 121 drug names were reviewed for inclusion, with 19 drugs from 18 innovative pharmaceutical companies successfully added to the directory, indicating a selection rate of approximately 15.7% [6][7] Group 7: CAR-T Therapies and Market Impact - Five CAR-T therapies were included in the first commercial health insurance innovative drug directory, which is expected to significantly reduce patient out-of-pocket expenses and improve accessibility [8][13] - The inclusion of CAR-T products is anticipated to have a positive ripple effect across the entire industry, enhancing market coverage and patient access [8][13]

Group 1 - The global rare disease patient population exceeds 300 million, with over 6,000 rare diseases identified, yet less than 5% have effective treatments available [1] - Advances in genomics and artificial intelligence are providing new hope for precise diagnosis and treatment of rare diseases [1][2] - The Hong Kong Genome Center has recruited over 53,000 participants since its full operation in 2021, aiming to establish a genomic database primarily for the South China population [1] Group 2 - The Greater Bay Area and Yangtze River Delta regions are witnessing the emergence of local leading companies in cell and gene therapy, such as BGI Genomics and Fosun Kite [2] - A three-year action plan was launched in May to develop common technology platforms in gene editing and organoids, with a special fund of 1 billion yuan to support cross-regional projects [2] - The importance of integrating multi-omics technologies into diagnostic laboratories is emphasized, alongside the need for data sharing and AI technologies [2] Group 3 - Beijing Union Medical College Hospital is enhancing rare disease diagnosis through data sharing and large model technology, significantly improving diagnostic efficiency [3] - The establishment of a national rare disease diagnosis collaboration network and the development of AI-assisted diagnostic tools have been key innovations in improving treatment efficiency [3] - The International Rare Disease Association and the Hong Kong Genome Center co-hosted a conference that attracted nearly 300 medical professionals and researchers from over 20 countries, focusing on clinical genetics, genomics, and data sharing [3]

Summary of Passage Bio FY Conference Call Company Overview - **Company**: Passage Bio (NasdaqGS:PASG) - **Industry**: Gene Therapy - **Focus**: Lead clinical program in frontotemporal dementia (FTD) with a granular mutation and a preclinical program in Huntington's disease [2][3] Key Points and Arguments Clinical Program Insights - **FTD Program**: The primary focus of the discussion was on the FTD program, particularly following a disappointing phase three study from a competitor [3][11] - **Progranulin Levels**: The company is investigating the significance of progranulin levels in the context of FTD GRN patients, noting that the average CSF progranulin level in a competitor's study was 4-5 ng/ml, while the normal range is 3-8 ng/ml [4][22] - **Mechanism of Action**: Passage Bio's approach involves using AAV (adeno-associated virus) to increase intracellular progranulin levels, contrasting with competitors that may inhibit natural cellular processes [8][25] Study Design and Patient Population - **Patient Selection**: The company plans to focus on earlier-stage patients (CDR 0.5 and 1) to enhance the likelihood of observing clinical responses, as opposed to including more severe patients [14][26] - **Epidemiology**: There are approximately 3,000 to 6,000 patients in the U.S. with FTD GRN, and genetic testing is crucial for early diagnosis [16][18] Regulatory Considerations - **FDA Guidance**: Recent FDA guidance indicates a potential openness to single-arm studies for rare diseases, which could benefit Passage Bio's registration strategy [21][29] - **Statistical Analysis Plan**: The company emphasizes the importance of prespecifying the statistical analysis plan and intends to engage with the FDA early in the study design process [28][29] Manufacturing and Financials - **Manufacturing**: The company collaborates with Catalent for manufacturing, utilizing a high productivity suspension process that can treat over 1,000 patients per batch [43][44] - **Cash Position**: Passage Bio has a cash balance sufficient to sustain operations into 2027, with an annual expenditure of approximately $30 million [45] Additional Important Insights - **Natural History Studies**: The company can leverage data from large natural history studies (All FTD and GenFi) to inform its clinical program [32] - **Neurofilament Biomarker**: The increase in plasma neurofilament levels observed in the study is consistent with age-related changes, suggesting the potential efficacy of the therapy [34][35] - **Future Data Release**: The company plans to refresh data in the first half of next year and will seek FDA guidance on the registration path, which is seen as a critical catalyst for investor confidence [39][40] This summary encapsulates the key aspects of Passage Bio's conference call, highlighting the company's strategic focus, clinical insights, regulatory considerations, and financial health.

Core Insights - The fourth "Jingcai Dachuang" Beijing University Student Innovation and Entrepreneurship Competition concluded with Beijing Forestry University's project on "Global Fault Leading Embodied Intelligent Specialized 42-Degree of Freedom Flexible Dexterous Hand Technology and Applications" winning the championship [1] - The competition attracted a record 8,468 entrepreneurial teams since its launch in March, establishing itself as a comprehensive innovation and entrepreneurship ecosystem platform [1] Group 1: Competition Highlights - Six elite teams showcased "hard technology" projects, including dexterous robotic hands, low-orbit satellite systems, and cross-species tumor gene therapy [2] - The champion team developed a dexterous hand that mimics human finger flexibility and durability, integrating a self-developed operating system and AI content generation system for full-chain automation [2] - Beijing University's "Greenvirosynergy" team created a novel gene therapy targeting prostate and bladder cancers, enhancing viral vector efficiency and targeting capabilities [2] Group 2: Investment Alliance Formation - The "Jingcai Dachuang Investment Alliance" was established to create a professional and ecological capital connection platform, facilitating the transformation of university scientific achievements [4] - The alliance aims to integrate market insights and investment logic into the selection process, providing a "financing express" and resource connection for excellent projects [4] - The initiative seeks to enhance the service chain for technology innovation results, promoting a two-way approach between university innovation resources and market demands [4] Group 3: Future Directions - The "Jingcai Dachuang" initiative will continue to deepen collaborative innovation practices among government, industry, academia, and research, focusing on event-driven support and ecosystem empowerment [5] - The goal is to enable more aspiring youth to shine on the broad stage of high-quality development in the capital [5]